File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Tyrosine kinase inhibitor STI571 in the treatment of Philadelphia chromosome-positive leukemia failing myeloablative stem cell transplantation

TitleTyrosine kinase inhibitor STI571 in the treatment of Philadelphia chromosome-positive leukemia failing myeloablative stem cell transplantation
Authors
KeywordsPh + Leukemia Relapse
Stem Cell Transplantation
STI571
Issue Date2002
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bmt
Citation
Bone Marrow Transplantation, 2002, v. 30 n. 7, p. 453-457 How to Cite?
AbstractEight patients with Philadelphia chromosome-positive (Ph +) leukaemia relapsing from stem cell transplantation (SCT) (one syngeneic and seven allogeneic) were treated with the tyrosine kinase inhibitor ST1571. Five patients relapsing as chronic myeloid leukaemia (CML) in chronic phase achieved a complete haematological response, with complete and major cytogenetic responses occurring in four and one cases, respectively. One patient became negative for BCR/ABL in the bone marrow. Three patients relapsed as acute leukaemia (two CML in myeloblastic crisis and one Ph + acute lymphoblastic leukaemia), all of whom achieved haematological and cytogenetic responses. One patient also became BCR/ABL negative. However, pancytopenia and graft-versus-host disease led to cessation of treatment in the remaining two cases, which was followed by disease recurrence refractory to further STI treatment. Our results showed that Ph + leukaemic relapses after SCT might respond well to STI571 therapy.
Persistent Identifierhttp://hdl.handle.net/10722/162635
ISSN
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 1.318
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_US
dc.contributor.authorLie, AKWen_US
dc.contributor.authorMa, SKen_US
dc.contributor.authorWan, TSen_US
dc.contributor.authorLiang, Ren_US
dc.contributor.authorChan, ECen_US
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2012-09-05T05:21:54Z-
dc.date.available2012-09-05T05:21:54Z-
dc.date.issued2002en_US
dc.identifier.citationBone Marrow Transplantation, 2002, v. 30 n. 7, p. 453-457en_US
dc.identifier.issn0268-3369en_US
dc.identifier.urihttp://hdl.handle.net/10722/162635-
dc.description.abstractEight patients with Philadelphia chromosome-positive (Ph +) leukaemia relapsing from stem cell transplantation (SCT) (one syngeneic and seven allogeneic) were treated with the tyrosine kinase inhibitor ST1571. Five patients relapsing as chronic myeloid leukaemia (CML) in chronic phase achieved a complete haematological response, with complete and major cytogenetic responses occurring in four and one cases, respectively. One patient became negative for BCR/ABL in the bone marrow. Three patients relapsed as acute leukaemia (two CML in myeloblastic crisis and one Ph + acute lymphoblastic leukaemia), all of whom achieved haematological and cytogenetic responses. One patient also became BCR/ABL negative. However, pancytopenia and graft-versus-host disease led to cessation of treatment in the remaining two cases, which was followed by disease recurrence refractory to further STI treatment. Our results showed that Ph + leukaemic relapses after SCT might respond well to STI571 therapy.en_US
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bmten_US
dc.relation.ispartofBone Marrow Transplantationen_US
dc.subjectPh + Leukemia Relapseen_US
dc.subjectStem Cell Transplantationen_US
dc.subjectSTI571en_US
dc.titleTyrosine kinase inhibitor STI571 in the treatment of Philadelphia chromosome-positive leukemia failing myeloablative stem cell transplantationen_US
dc.typeArticleen_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1038/sj.bmt.1703678en_US
dc.identifier.pmid12368958-
dc.identifier.scopuseid_2-s2.0-0036775905en_US
dc.identifier.hkuros77823-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036775905&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume30en_US
dc.identifier.issue7en_US
dc.identifier.spage453en_US
dc.identifier.epage457en_US
dc.identifier.isiWOS:000178828300008-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridAu, WY=7202383089en_US
dc.identifier.scopusauthoridLie, AKW=24284842400en_US
dc.identifier.scopusauthoridMa, SK=9042504200en_US
dc.identifier.scopusauthoridWan, TS=25623981600en_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridChan, EC=7401994120en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US
dc.identifier.issnl0268-3369-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats